The study will include up to 1,420 participants ages 18-55 across three cohorts, according to a news release.
The first cohort includes 615 participants who received two doses of Pfizer’s original COVID-19 vaccine 90-180 days prior to enrollment. They will receive one or two doses of the omicron-specific vaccine.
The second cohort includes 600 participants who received three doses of Pfizer’s original COVID-19 vaccine 90-180 days prior to enrollment. They will receive one dose of the original vaccine or the omicron-specific vaccine.
The third cohort includes 205 unvaccinated participants. They will receive three doses of the omicron-specific vaccine.
Read Pfizer’s release here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
